All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

    KCE Reports 240 (2015)

    https://kce.fgov.be/en/next-generation-sequencing-gene-panels-for-targeted-therapy-in-oncology-and-haemato-oncology

  2. Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers

    KCE Reports 235 (2015)

    https://kce.fgov.be/en/hadron-therapy-in-children-%E2%80%93-an-update-of-the-scientific-evidence-for-15-paediatric-cancers

  3. The non-invasive prenatal test (NIPT) for trisomy 21 – health economic aspects

    KCE Reports 222 (2014)

    https://kce.fgov.be/en/the-non-invasive-prenatal-test-nipt-for-trisomy-21-%E2%80%93-health-economic-aspects

  4. Innovative radiotherapy techniques: a multicentre time-driven activity-based costing study

    KCE Reports 198 (2013)

    https://kce.fgov.be/en/innovative-radiotherapy-techniques-a-multicentre-time-driven-activity-based-costing-study
  5. Hepatitis C: Screening en Preventie

    [Hepatitis C: Screening and Prevention]

    KCE Reports 173 (2012)

    https://kce.fgov.be/en/hepatitis-c-screening-and-prevention

  6. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  7. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

    KCE Reports 127 (2010)

    https://kce.fgov.be/en/cost-effectiveness-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium-part-1-literature-review

  8. Pharmaceutical and non-pharmaceutical interventions for Alzheimer’s Disease, a rapid assessment

    KCE Reports 111 (2009)

    https://kce.fgov.be/en/pharmaceutical-and-non-pharmaceutical-interventions-for-alzheimer%E2%80%99s-disease-a-rapid-assessment

  9. HPV Vaccination for the Prevention of Cervical Cancer in Belgium: Health Technology Assessment

    KCE Reports 64 (2007)

    https://kce.fgov.be/en/hpv-vaccination-for-the-prevention-of-cervical-cancer-in-belgium-health-technology-assessment

  10. Intensity-modulated radiotherapy (IMRT)

    KCE Reports 62 (2007)

    https://kce.fgov.be/en/intensity-modulated-radiotherapy-imrt

  11. Cervical Cancer Screening and Human Papillomavirus (HPV) Testing

    KCE Reports 38 (2006) 2nd print (1st print, September 2006)

    https://kce.fgov.be/en/cervical-cancer-screening-and-human-papillomavirus-hpv-testing

  12. Trastuzumab in Early Stage Breast Cancer

    KCE Reports 34 (2006) 30 June (2nd edition; 22 June 2006, 1st edition)

    https://kce.fgov.be/en/trastuzumab-in-early-stage-breast-cancer

  13. [Capsule endoscopy]

    KCE Reports 25 (2006)

    https://kce.fgov.be/en/capsule-endoscopy

  14. [Molecular Diagnostics in Belgium]

    KCE Reports 20 (2005)

    https://kce.fgov.be/en/molecular-diagnostics-in-belgium

  15. Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

    KCE Reports 276 (2016)

    https://kce.fgov.be/en/economic-evaluation-of-novel-direct-acting-antiviral-daa-treatment-strategies-for-chronic-hepatitis
  16. Illustration report 298

    MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer

    KCE Report 298 (2018) Breast cancer is the most commonly diagnosed cancer in women in Belgium and throughout the world. Provided this cancer is in the early stage, treatment is essentially locoregional, that is, via surgery alone or combined with radiation therapy. In theory, this treatment is enough to eradicate the tumour since it is still limited. However, it is known that about 30% of patients treated in this way are at risk of developing remote metastases, because metastatic cancerous cells are already present but undetectable at the time of diagnosis.

    https://kce.fgov.be/en/mammaprint%C2%AE-test-for-personalised-management-of-adjuvant-chemotherapy-decisions-in-early-breast